文献速递生殖医学

欧洲国家ART与IUI的调查:立法、监管、资助和登记——更新

Survey on ART and IUI: legislation, regulation, funding, and registries in European countries-an update.
PubMed 文献 · Hum Reprod · 2024-01-01

该调查通过问卷收集43个欧洲国家截至2022年12月31日ART和IUI的立法、资助和登记情况,发现仅39国有专门立法,公共资助差异大(4国缺乏或极少),33国有国家登记系统,与上次调查相比变化较小,多朝提高可及性方向。

要点

  • 43个开展ART和IUI的欧洲国家中,39国有专门立法,33国将人工授精视为ART技术。
  • 仅8国将可及性限于不育夫妇,33国允许单身女性接受治疗,19国允许女性伴侣接受治疗。
  • 公共资助体系差异极大,1国不提供资助,3国仅提供最低支持,多数国家设定年龄等资助限制。

核心结论

  • 欧洲43个开展ART和IUI的国家中,仅39国有专门立法,公共资助在各国之间及国内差异大(4国缺乏或极少),33国有国家登记系统。
  • 与2018年调查相比仅发现少量变化,多数朝提高可及性方向,通过增加公共财政支持和/或开放额外亚组。

研究设计与样本

  • 使用SurveyMonkey工具设计问卷,包含90个问题,覆盖法律、资助和登记等领域,并考虑第三方捐赠的具体细节。
  • 邀请所有EIM成员参与,答案经核查并与初始应答者澄清不清之处,汇总数据表发送至ESHRE国家代表委员会成员进行二次检查。
  • 信息来自45个开展ART和IUI的欧洲国家中的43个,答案反映各国2022年12月31日的情况。

主要发现

  • 39国有ART专门立法,33国将人工授精视为ART技术;8国可及性仅限不育夫妇。
  • 5国允许单身女性和所有同性伴侣接受治疗,33国允许单身女性,19国允许女性伴侣。
  • 除2国外均允许使用捐赠精子,38国允许卵母细胞捐赠,32国允许精子和卵母细胞同时捐赠,29国允许胚胎捐赠。
  • PGT-M/SR在3国不允许,PGT-A在10国不允许,15国接受代孕。
  • 女性最低年龄通常为18岁,最高年龄范围42至54岁,部分国家无数字定义;男性最高年龄极少国家设定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 尽管回答由知情且投入的个人提供并经过双重检查,但没有官方机构的正式验证,因此不能排除可能存在的不准确。
  • 结果是一个时间横断面,欧洲国家的ART和IUI框架持续修改。
  • ART活动的某些领域被有意排除在调查范围之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How are ART and IUI regulated, funded, and registered in European countries, and how has the situation changed since 2018? SUMMARY ANSWER: Of the 43 countries performing ART and IUI in Europe, and participating in the survey, specific legislation exists in only 39 countries, public funding varies across and sometimes within countries (and is lacking or minimal in four countries), and national registries are in place in 33 countries; only a small number of changes were identified, most of them in the direction of improving accessibility, through increased public financial support and/or opening access to additional subgroups. WHAT IS KNOWN ALREADY: The annual reports of the European IVF-Monitoring Consortium (EIM) clearly show the existence of different approaches across Europe regarding accessibility to and efficacy of ART and IUI treatments. In a previous survey, some coherent information was gathered about how those techniques were regulated, funded, and registered in European countries, showing that diversity is the paradigm in this medical field. STUDY DESIGN, SIZE, DURATION: A survey was designed using the SurveyMonkey tool consisting of 90 questions covering several domains (legal, funding, and registry) and considering specific details on the situation of third-party donations. New questions widened the scope of the previous survey. Answers refer to the situation of countries on 31 December 2022. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: All members of the EIM were invited to participate. The received answers were checked and initial responders were asked to address unclear answers and to provide any additional information considered relevant. Tables resulting from the consolidated data were then sent to members of the Committee of National Representatives of ESHRE, requesting a second check. Conflicting information was clarified by direct contact. MAIN RESULTS AND THE ROLE OF CHANCE: Information was received from 43 out of the 45 European countries where ART and IUI are performed. There were 39 countries with specific legislation on ART, and artificial insemination was considered an ART technique in 33 of them. Accessibility is limited to infertile couples only in 8 of the 43 countries. In 5 countries, ART and IUI are permitted also for treatments of single women and all same sex couples, while a total of 33 offer treatment to single women and 19 offer treatment to female couples. Use of donated sperm is allowed in all except 2 countries, oocyte donation is allowed in 38, simultaneous donation of sperm and oocyte is allowed in 32, and embryo donation is allowed in 29 countries. Preimplantation genetic testing (PGT)-M/SR (for monogenetic disorders, structural rearrangements) is not allowed in 3 countries and PGT-A (for aneuploidy) is not allowed in 10; surrogacy is accepted in 15 countries. Except for marital/sexual situation, female age is the most frequently reported limiting criterion for legal access to ART: minimal age is usually set at 18 years and the maximum ranges from 42 to 54 with some countries not using numeric definition. Male maximum age is set in very few countries. Where third-party donors are permitted, age is frequently a limiting criterion (male maximum age ranging from 35 to 50; female maximum age from 30 to 37). Other legal restrictions in third-party donation are the number of children born from the same donor (or, in some countries, the number of families with children from the same donor) and, in 12 countries, there is a maximum number of oocyte donations. How countries deal with the anonymity is diverse: strict anonymity, anonymity just for the recipients (not for children when reaching legal adulthood age), a mixed system (anonymous and non-anonymous donations), and strict non-anonymity. Inquiring about donors' genetic screening showed that most countries have enforced either mandatory or scientific recommendations that exclude the most prevalent genetic diseases, although, again, diversity is evident. Reimbursement/compensation systems exist in more than 30 European countries, with around 10 describing clearly defined maximum amounts considered acceptable. Public funding systems are extremely variable. One country provides no financial assistance to ART/IUI patients and three offer only minimal support. Limits to the provision of funding are defined in the others i.e. age (female maximum age is the most used), existence of previous children, BMI, maximum number of treatments publicly supported, and techniques not entitled for funding. In a few countries reimbursement is linked to a clinical policy. The definitions of the type of expenses covered within an IVF/ICSI cycle, up to which limit, and the proportion of out-of-pocket costs for patients are also extremely dissimilar. National registries of ART are in place in 33 out of the 43 countries contributing to the survey and a registry of donors exists in 19 of them. When comparing with the results of the previous survey, the main changes are: (i) an extension of the beneficiaries of ART techniques (and IUI), evident in nine countries; (ii) public financial support exists now in Albania and Armenia; (iii) in Luxembourg, the only ART centre expanded its on-site activities; (iv) donor-conceived children are entitled to know the donor identity in six countries more than in 2018; and (v) four more countries have set a maximum number of oocyte donations. LIMITATIONS, REASONS FOR CAUTION: Although the responses were provided by well-informed and committed individuals and submitted to double checking, no formal validation by official bodies was in place. Therefore, possible inaccuracies cannot be excluded. The results presented are a cross-section in time, and ART and IUI frameworks within European countries undergo continuous modification. Finally, some domains of ART activity were deliberately left out of the scope of this survey. WIDER IMPLICATIONS OF THE FINDINGS: Our results offer a detailed updated view of the ART and IUI situation in European countries. It provides extensive answers to many relevant questions related to ART usage at the national level and could be used by institutions and policymakers at both national and European levels. STUDY FUNDING/COMPETING INTEREST(S): The study has no external funding, and all costs were covered by ESHRE. There were no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Calhaz-Jorge C, Smeenk J, Wyns C, et al. Survey on ART and IUI: legislation, regulation, funding, and registries in European countries-an update. Hum Reprod. 2024. PMID: 39043375. doi:10.1093/humrep/deae163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。